English

INMED PHARMACEUTICALS INC.

EDGAR

INM Annual report (10-K) · filed 2026-09-09

Annual consolidated revenue for 2025: about USD 4.943M, using the latest reported figures. The previous period, 2024, was about USD 4.598M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

820 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 820188 USD Source

Operating cash flow

-2.38 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -3983859 USD Source
Operating Cash Flow: -1607616 USD Source

Cash and cash equivalents: 5.16 million USD 2026-03-31 Source
Exact value

5158932 USD
Long-term debt including current maturities: Not available
Shares outstanding: 5.34 million uref_1778804852 2026-06-30 Source
Exact value

5339436 uref_1778804852

Reported share-count change

166.68% · 3.34 million uref_1778804852

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

2002186 uref_1778804852 · 2025-06-30· Source
5339436 uref_1778804852 · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

4.51 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 1261578 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 4942633 USD · 2024-07-01 – 2025-06-30 Source
Revenue: 3637923 USD · 2024-07-01 – 2025-03-31 Source
Revenue: 1120121 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 820188 USD · 2025-10-01 – 2025-12-31 Source

Operating cash flow

-7.46 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -7766951 USD · 2024-07-01 – 2025-06-30 Source
Operating cash flow: -5988445 USD · 2024-07-01 – 2025-03-31 Source
Operating cash flow: -1607616 USD · 2025-07-01 – 2025-09-30 Source
Operating cash flow: -3983859 USD · 2025-07-01 – 2025-12-31 Source
Operating cash flow: -1607616 USD · 2025-07-01 – 2025-09-30 Source
Operating cash flow: -5678995 USD · 2025-07-01 – 2026-03-31 Source
Operating cash flow: -3983859 USD · 2025-07-01 – 2025-12-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-09.

Financial data available through: 2025-06-30.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-06-30
Operating income: 3 of 11 periods available· newest 2023-06-30
Net income: Multiple units; comparison withheld· newest 2025-06-30
Operating cash flow: Multiple units; comparison withheld· newest 2025-06-30
Capital expenditure: 5 of 11 periods available· newest 2024-06-30
Total assets: Multiple units; comparison withheld· newest 2025-06-30
Total liabilities: Multiple units; comparison withheld· newest 2025-06-30
Current assets: Multiple units; comparison withheld· newest 2025-06-30
Current liabilities: Multiple units; comparison withheld· newest 2025-06-30
Cash and cash equivalents: 5 of 11 periods available· newest 2025-06-30
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+7.5%

Prior period

USD 4.6 million

2023-07-01 – 2024-06-30
Current period

USD 4.94 million

2024-07-01 – 2025-06-30

Exact inputs and evidence

4942633 − 4597730 = 344903 USD

4597730 USD · 2023-07-01 – 2024-06-30
Inspect prior input Prior source
4942633 USD · 2024-07-01 – 2025-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · INMED PHARMACEUTICALS INC. · 2025-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Year-over-year change in Revenue: 344903 USD Concept: fundies:Revenue Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4942633 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1109418 Filing: 000121390025090210 Input fundies:Revenue: 4597730 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1110042 Filing: 000121390025090210
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 500,000

Prior period

−USD 7.7 million

2023-07-01 – 2024-06-30
Current period

−USD 8.2 million

2024-07-01 – 2025-06-30

Exact inputs and evidence

-8200000 − -7700000 = -500000 USD

-7700000 USD · 2023-07-01 – 2024-06-30
Inspect prior input Prior source
-8200000 USD · 2024-07-01 – 2025-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · INMED PHARMACEUTICALS INC. · 2025-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Year-over-year change in Net income: -500000 USD Concept: fundies:NetIncome Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -8200000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1286353 Filing: 000121390025090210 Input fundies:NetIncome: -7700000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1286544 Filing: 000121390025090210
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 781,119

Prior period

−USD 6.99 million

2023-07-01 – 2024-06-30
Current period

−USD 7.77 million

2024-07-01 – 2025-06-30

Exact inputs and evidence

-7766951 − -6985832 = -781119 USD

-6985832 USD · 2023-07-01 – 2024-06-30
Inspect prior input Prior source
-7766951 USD · 2024-07-01 – 2025-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · INMED PHARMACEUTICALS INC. · 2025-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Year-over-year change in Operating cash flow: -781119 USD Concept: fundies:OperatingCashFlow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -7766951 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1243453 Filing: 000121390025090210 Input fundies:OperatingCashFlow: -6985832 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1244186 Filing: 000121390025090210
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2024-07-01 – 2025-06-30

Revenue USD 4.94 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2020-07-01 – 2021-06-30	1904013	12107102 Derived	-10203089	Unavailable	Unavailable	Unavailable	Source 2020-07-01 – 2021-06-30: 1904013 USD Inspect Revenue Open source 2020-07-01 – 2021-06-30: -10203089 USD Inspect Operating Income Open source 2020-07-01 – 2021-06-30: 1725 USD Inspect Capital Expenditure Open source
2022 2021-07-01 – 2022-06-30	1089435	19689552 Derived	-18600117	Unavailable	Unavailable	Unavailable	Source 2021-07-01 – 2022-06-30: 1089435 USD Inspect Revenue Open source 2021-07-01 – 2022-06-30: -18600117 USD Inspect Operating Income Open source 2021-07-01 – 2022-06-30: 39108 USD Inspect Capital Expenditure Open source
2023 2022-07-01 – 2023-06-30	4135561	12083183 Derived	-7947622	Unavailable	Unavailable	Unavailable	Source 2022-07-01 – 2023-06-30: 4135561 USD Inspect Revenue Open source 2022-07-01 – 2023-06-30: -7947622 USD Inspect Operating Income Open source 2022-07-01 – 2023-06-30: 160014 USD Inspect Capital Expenditure Open source
2024 2023-07-01 – 2024-06-30	4597730	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2023-07-01 – 2024-06-30: 4597730 USD Inspect Revenue Open source 2023-07-01 – 2024-06-30: 9293 USD Inspect Capital Expenditure Open source
2025 2024-07-01 – 2025-06-30	4942633	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2024-07-01 – 2025-06-30: 4942633 USD Inspect Revenue Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 4.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-06-30	Revenue	1904013	Revenue: 1904013 Open source
20222022-06-30	Revenue	1089435	Revenue: 1089435 Open source
20232023-06-30	Revenue	4135561	Revenue: 4135561 Open source
20242024-06-30	Revenue	4597730	Revenue: 4597730 Open source
20252025-06-30	Revenue	4942633	Revenue: 4942633 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

7.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-06-30	Year over year	No prior comparable period	Revenue: 1904013 Open source
20222022-06-30	Year over year	-42.8%	Revenue: 1089435 Open source Revenue: 1904013 Open source
20232023-06-30	Year over year	279.6%	Revenue: 4135561 Open source Revenue: 1089435 Open source
20242024-06-30	Year over year	11.2%	Revenue: 4597730 Open source Revenue: 4135561 Open source
20252025-06-30	Year over year	7.5%	Revenue: 4942633 Open source Revenue: 4597730 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -192.2% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-06-30	Operating margin	-535.9%	Operating Income: -10203089 Open source Revenue: 1904013 Open source
20222022-06-30	Operating margin	-1,707.3%	Operating Income: -18600117 Open source Revenue: 1089435 Open source
20232023-06-30	Operating margin	-192.2%	Operating Income: -7947622 Open source Revenue: 4135561 Open source
2024-06-30	Operating margin	Not reported	Revenue: 4597730 Open source
2025-06-30	Operating margin	Not reported	Revenue: 4942633 Open source
2021-06-30	Net margin	Not reported	Revenue: 1904013 Open source
2022-06-30	Net margin	Not reported	Revenue: 1089435 Open source
2023-06-30	Net margin	Not reported	Revenue: 4135561 Open source
2024-06-30	Net margin	Not reported	Revenue: 4597730 Open source
2025-06-30	Net margin	Not reported	Revenue: 4942633 Open source
20212021-06-30	Free cash flow margin	Not reported	Revenue: 1904013 Open source Capital Expenditure: 1725 Open source
20222022-06-30	Free cash flow margin	Not reported	Revenue: 1089435 Open source Capital Expenditure: 39108 Open source
20232023-06-30	Free cash flow margin	Not reported	Revenue: 4135561 Open source Capital Expenditure: 160014 Open source
20242024-06-30	Free cash flow margin	Not reported	Revenue: 4597730 Open source Capital Expenditure: 9293 Open source
20252025-06-30	Free cash flow margin	Not reported	Revenue: 4942633 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-06-30	Operating cash flow	Not reported	No source recorded
20222022-06-30	Operating cash flow	Not reported	No source recorded
20232023-06-30	Operating cash flow	Not reported	No source recorded
20242024-06-30	Operating cash flow	Not reported	No source recorded
20252025-06-30	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-06-30	Free cash flow	Unavailable	Capital Expenditure: 1725 Open source
20222022-06-30	Free cash flow	Unavailable	Capital Expenditure: 39108 Open source
20232023-06-30	Free cash flow	Unavailable	Capital Expenditure: 160014 Open source
20242024-06-30	Free cash flow	Unavailable	Capital Expenditure: 9293 Open source
20252025-06-30	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2021-06-30	Liabilities / assets	Not reported	No source recorded
2022-06-30	Liabilities / assets	Not reported	No source recorded
2023-06-30	Liabilities / assets	Not reported	No source recorded
2024-06-30	Liabilities / assets	Not reported	No source recorded
2025-06-30	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2021-06-30	Current assets / current liabilities	Not reported	No source recorded
2022-06-30	Current assets / current liabilities	Not reported	No source recorded
2023-06-30	Current assets / current liabilities	Not reported	No source recorded
2024-06-30	Current assets / current liabilities	Not reported	No source recorded
2025-06-30	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2019-07-01 – 2020-06-30	Unavailable Not reported for this period.	Unavailable Not reported for this period.	USD 42,573 Exact value Exact value: 42573 USD 2019-07-01 – 2020-06-30: 42573 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INMED PHARMACEUTICALS INC. · 2020-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Capital Expenditure: 42573 USD Concept: fundies:CapitalExpenditure Period: 2019-07-01 to 2020-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328/explain?concept=fundies%3ACapitalExpenditure&period=2020-06-30&surface=latest&period_type=duration&start=2019-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 42573 USD (2019-07-01 to 2020-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390021049679/f10k2021_inmedpharma.htm#1043422 Filing: 000121390021049679 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2021 2020-07-01 – 2021-06-30	Unavailable Not reported for this period.	Unavailable Not reported for this period.	USD 1,725 Exact value Exact value: 1725 USD 2020-07-01 – 2021-06-30: 1725 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INMED PHARMACEUTICALS INC. · 2021-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Capital Expenditure: 1725 USD Concept: fundies:CapitalExpenditure Period: 2020-07-01 to 2021-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328/explain?concept=fundies%3ACapitalExpenditure&period=2021-06-30&surface=latest&period_type=duration&start=2020-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1725 USD (2020-07-01 to 2021-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390022058355/f10k2022_inmedpharma.htm#1292359 Filing: 000121390022058355 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2022 2021-07-01 – 2022-06-30	Unavailable Not reported for this period.	Unavailable Not reported for this period.	USD 39,108 Exact value Exact value: 39108 USD 2021-07-01 – 2022-06-30: 39108 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INMED PHARMACEUTICALS INC. · 2022-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Capital Expenditure: 39108 USD Concept: fundies:CapitalExpenditure Period: 2021-07-01 to 2022-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328/explain?concept=fundies%3ACapitalExpenditure&period=2022-06-30&surface=latest&period_type=duration&start=2021-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 39108 USD (2021-07-01 to 2022-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390023080842/f10k2023_inmedpharma.htm#1048136 Filing: 000121390023080842 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2023 2022-07-01 – 2023-06-30	Unavailable Not reported for this period.	Unavailable Not reported for this period.	USD 160,014 Exact value Exact value: 160014 USD 2022-07-01 – 2023-06-30: 160014 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INMED PHARMACEUTICALS INC. · 2023-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Capital Expenditure: 160014 USD Concept: fundies:CapitalExpenditure Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328/explain?concept=fundies%3ACapitalExpenditure&period=2023-06-30&surface=latest&period_type=duration&start=2022-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 160014 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390024082843/ea0214241-10k_inmed.htm#908584 Filing: 000121390024082843 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2024 2023-07-01 – 2024-06-30	Unavailable Not reported for this period.	Unavailable Not reported for this period.	USD 9,293 Exact value Exact value: 9293 USD 2023-07-01 – 2024-06-30: 9293 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INMED PHARMACEUTICALS INC. · 2024-06-30 INMED PHARMACEUTICALS INC. (edgar:1728328) Capital Expenditure: 9293 USD Concept: fundies:CapitalExpenditure Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T22:21:24Z Snapshot: 8968883b25092b2b6ef083be6832659469421059d7383c228ebab289eb6ab7c2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1728328/explain?concept=fundies%3ACapitalExpenditure&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9293 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm#1247486 Filing: 000121390025090210 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

43 filings · 1,838 latest values · 1,838 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001728328, 1728328, INM, edgar:1728328

Also known as INMED PHARMACEUTICALS INC., INMED PHARMACEUTICALS INC., InMed Pharmaceuticals Inc.

INMED PHARMACEUTICALS INC.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2024-07-01 – 2025-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation